ReviewFrontiers in immunology2019
The Evolution of T Cell Depleted Haploidentical Transplantation.
Review in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 38 citations in OpenAlex.
- Pharmacokinetics of alemtuzumab in pediatric patients undergoing ex vivo T-cell-depleted haploidentical hematopoietic cell transplantation.Cancer chemotherapy and pharmacology · 2020Trial
- Clinical relevance of feto-maternal microchimerism in (hematopoietic stem cell) transplantation.Seminars in immunopathology · 2024Review
- Comparison of Cyclophosphamide-Based Graft Versus Host Disease Prophylaxis after "Allogeneic Stem Cell Transplantation from 9/10 HLA Matched Unrelated Donor'' with Standard Graft Versus Host Disease Prophylaxis after "10/10 HLA Matched Relative Donor'' Transplant.International journal of hematology-oncology and stem cell research · 2024Article
- Stem cell transplantation for ALL: you've always got a donor, why not always use it?Hematology. American Society of Hematology. Education Program · 2023Review
- Review
- Article
- Current status and prospects of hematopoietic stem cell transplantation in China.Chinese medical journal · 2022Review
- A Deep Insight Into Regulatory T Cell Metabolism in Renal Disease: Facts and Perspectives.Frontiers in immunology · 2022Review
- Is Post-Transplant Cyclophosphamide the New Methotrexate?Journal of clinical medicine · 2021Review
- Real-world experience: Introduction of T cell replete haploidentical transplantations in a single center.EJHaem · 2021Article
- A concise review on factors influencing the hematopoietic stem cell transplantation main outcomes.Health science reports · 2021Review
- Advances in preclinical hematopoietic stem cell models and possible implications for improving therapeutic transplantation.Stem cells translational medicine · 2021Review
- Immune Therapies for Hematologic Malignancies.Cancers · 2021Article
- HLA-Haploidentical Family Donors: The New Promise for Childhood Acute Lymphoblastic Leukaemia?Frontiers in pediatrics · 2021Review
- Haploidentical Stem Cell Transplantation for Acute Myeloid Leukemia: Current Therapies, Challenges and Future Prospective.Frontiers in oncology · 2021Review
- Novel Immune Cell-Based Therapies to Eradicate High-Risk Acute Myeloid Leukemia.Frontiers in immunology · 2021Review
- Article
- Injury intensifies T cell mediated graft-versus-host disease in a humanized model of traumatic brain injury.Scientific reports · 2020Article
- Mechanisms of Leukemia Immune Evasion and Their Role in Relapse After Haploidentical Hematopoietic Cell Transplantation.Frontiers in immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Work on bone marrow transplantation from haploidentical donor has been proceeding for over 20 years all over the world and new transplant procedures have been developed. To control both graft rejection and graft vs. host disease, some centers have preferred to enhance the intensity of the conditioning regimens and the post-transplant immune suppression in the absence of graft manipulation; others have concentrated on manipulating the graft in the absence of any additional post-transplant immune suppressive agent. Due to the current high engraftment rates, the low incidence of graft-vs.-host disease and regimen related mortality, transplantation from haploidentical donors have been progressively offered even to elderly patients. Overall, survivals compare favorably with reports on transplants from unrelated donors. Further improvements will come with successful implementation of strategies to enhance post-transplant immune reconstitution and to prevent leukemia relapse.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.